This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 3.92% and 2.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -28.13% and 26.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Lags Q1 Earnings Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 14% and 2.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Can LivaNova (LIVN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
LivaNova (LIVN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Accuray (ARAY) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -100% and 10.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 51.11% and 3.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
LivaNova (LIVN) has been struggling lately, but the selling pressure may be coming to an end soon.
LivaNova (LIVN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 62.50% and 9.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 133.33% and 6.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Tops Q4 Earnings Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 7.58% and -0.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: LivaNova (LIVN) Q4 Earnings Expected to Decline
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 80.95% and 8.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: LivaNova (LIVN) Q3 Earnings Expected to Decline
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
LivaNova (LIVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 50.00% and 6.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Lags Q1 Earnings Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of -2.94% and 3.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Q4 Earnings Top Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 5.26% and -1.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Q3 Earnings Surpass Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 16.67% and -1.55%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Oct 30 Earnings Roster: MCK, MASI & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.